AI Models Achieve 85% Accuracy Predicting Clinical Trial Outcomes Before First Patient Enrolled
IQVIA's new predictive platform, powered by NVIDIA technology, promises to help drugmakers identify protocol flaws and optimize trial design through virtual simulation.
When Anonymous Patient Data Isn't Anonymous: Italy's €7M Fine Exposes the Pseudonymization Trap in Healthcare AI
Italy's data regulator ruled that IQVIA's longitudinal database of one million patients was identifiable personal data, not anonymous information—challenging a core assumption underpinning real-world evidence collection for pharmaceutical research and AI training.
IQVIA Promises to Slash Clinical Trial Startup Times by One-Third Using AI Platform
Healthcare giant unveils predictive development system claiming 33% faster study launches and 1.7x patient recruitment boost through automation and machine learning.
How AI Slashed Diabetes Chart Reviews from 60,000 to 300 While Boosting Detection 127-Fold
IQVIA's award-winning clinical decision support tool demonstrates unprecedented efficiency gains in identifying adults misdiagnosed with type 1 diabetes, reducing clinician workload by 99.5% while dramatically improving diagnostic accuracy.
The Validation Gap: Why AI-Designed Antibodies Just Hit Their First Real-World Reality Check
A landmark Nature Biotechnology benchmark reveals wildly inconsistent performance across 29 organizations' AI platforms, exposing the fragile evidence base beneath computational drug discovery's regulatory future.
Eli Lilly Bets on Veeva's AI Agents to Power Global GLP-1 Commercial Blitz
As Lilly's revenue surges 48% on blockbuster obesity drugs, the pharma giant commits to deploying Veeva's \"agentic commercial\" AI framework worldwide to manage field engagement at unprecedented scale.